drugset / Trial / NCT06421610
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
NaSingle-groupOpen-labelSupportive care
Summary
This study will monitor and evaluate patient and personnel safety and toxicity during the implementation and evaluation of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) directed treatment. Furthermore, this study will focus on Quality of Life questionnaires, LENT score, and evaluate pain and breathlessness using af visual analogue scales (VAS).
Timeline
- Start
- 2023-09-15
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 10.5 mg/m2 | Intrathecal |
| Subject | Doxorubicin | Other / unclassified | 2.1 mg/m2 | Intrathecal |
| Subject | Oxaliplatin | Small molecule | 92 mg/m2 | Intrathecal |